JP2019531279A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531279A5
JP2019531279A5 JP2019512859A JP2019512859A JP2019531279A5 JP 2019531279 A5 JP2019531279 A5 JP 2019531279A5 JP 2019512859 A JP2019512859 A JP 2019512859A JP 2019512859 A JP2019512859 A JP 2019512859A JP 2019531279 A5 JP2019531279 A5 JP 2019531279A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
compound according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531279A (ja
JP7042804B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052106 external-priority patent/WO2018053447A1/en
Publication of JP2019531279A publication Critical patent/JP2019531279A/ja
Publication of JP2019531279A5 publication Critical patent/JP2019531279A5/ja
Application granted granted Critical
Publication of JP7042804B2 publication Critical patent/JP7042804B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512859A 2016-09-19 2017-09-18 ピペラジンカルバメート、及びその製造と使用の方法 Active JP7042804B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662396561P 2016-09-19 2016-09-19
US62/396,561 2016-09-19
PCT/US2017/052106 WO2018053447A1 (en) 2016-09-19 2017-09-18 Piperazine carbamates and methods of making and using same

Publications (3)

Publication Number Publication Date
JP2019531279A JP2019531279A (ja) 2019-10-31
JP2019531279A5 true JP2019531279A5 (enExample) 2020-11-05
JP7042804B2 JP7042804B2 (ja) 2022-03-28

Family

ID=61619083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019512859A Active JP7042804B2 (ja) 2016-09-19 2017-09-18 ピペラジンカルバメート、及びその製造と使用の方法

Country Status (6)

Country Link
US (1) US10899737B2 (enExample)
EP (1) EP3515897B1 (enExample)
JP (1) JP7042804B2 (enExample)
CN (1) CN109996790B (enExample)
ES (1) ES2892952T3 (enExample)
WO (1) WO2018053447A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
WO2018053447A1 (en) 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
JOP20190106A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CN112088001A (zh) 2018-05-15 2020-12-15 隆德贝克拉荷亚研究中心有限公司 Magl抑制剂
JP2021531287A (ja) * 2018-07-19 2021-11-18 ファイザー・インク Magl阻害剤としての複素環式スピロ化合物
WO2021061858A1 (en) * 2019-09-25 2021-04-01 Frontier Medicines Corporation Targeted autophagy conjugates and methods
CA3159391A1 (en) * 2019-11-15 2021-05-20 H. Lundbeck A/S Crystalline forms of a magl inhibitor
IL297470A (en) * 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
US20250084065A1 (en) 2021-12-29 2025-03-13 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009363A (en) 1911-07-05 1911-11-21 Albert Winnie Artificial fishing-bait.
US1057010A (en) 1913-01-14 1913-03-25 Harry L Roderick Means for controlling doors and steps of cars.
FR1593586A (enExample) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
ATE138365T1 (de) 1991-11-27 1996-06-15 Du Pont Herbizide acylierte amino-(phenyl-oder-pyridinyl- oder thienyl-)phenyl derivate
AU1384795A (en) 1993-12-22 1995-07-10 Shell Internationale Research Maatschappij B.V. Process for preparing carbamates
EP0863879A1 (en) 1995-11-15 1998-09-16 Zeneca Limited Herbicidal substituted pyrazole compounds
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
EP1226115A4 (en) 1999-10-04 2006-03-15 Univ New Jersey Med NEW CARBAMATES AND UREES
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
AU2003300702A1 (en) 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Process for preparing carbamates
EP1716130A1 (en) 2004-02-18 2006-11-02 AstraZeneca AB Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
JP2008521768A (ja) 2004-12-23 2008-06-26 エフ.ホフマン−ラ ロシュ アーゲー ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用
EP2937341B1 (en) 2004-12-30 2017-07-05 Janssen Pharmaceutica N.V. 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎の治療方法
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
EP2124927A2 (en) 2007-02-26 2009-12-02 Kosan Biosciences Incorporated Carbamate compounds
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
AU2009270983A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and their use as GPCR modulators
AU2009314629B2 (en) 2008-11-14 2014-09-25 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
JP2012521425A (ja) 2009-03-23 2012-09-13 Msd株式会社 オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
TWI506011B (zh) 2009-11-03 2015-11-01 Bayer Materialscience Ag 在光聚合物調配物中作為添加劑之氟胺基甲酸酯
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
MX350788B (es) * 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
CA2860623A1 (en) 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP6100883B2 (ja) 2012-03-19 2017-03-22 アビデ セラピューティクス,インク. カルバマート化合物、及びその製造並びに使用
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
CA2917050A1 (en) 2013-07-03 2015-01-08 Todd K. Jones Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
US10570146B2 (en) 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
US9771341B2 (en) 2015-03-18 2017-09-26 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
WO2018053447A1 (en) 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2017361257B2 (en) 2016-11-16 2022-02-10 H. Lundbeck A/S. Crystalline forms of a MAGL inhibitor
US11161856B2 (en) 2017-08-29 2021-11-02 H. Lundbeck A/S Spirocycle compounds and methods of making and using same
CN112088001A (zh) 2018-05-15 2020-12-15 隆德贝克拉荷亚研究中心有限公司 Magl抑制剂

Similar Documents

Publication Publication Date Title
JP2019531279A5 (enExample)
JP2018529650A5 (enExample)
JP2019524883A5 (enExample)
JP2020530487A5 (enExample)
JP2020532547A5 (enExample)
JP2019034943A5 (enExample)
JP2020502047A5 (enExample)
JP2014511891A5 (enExample)
JP2020532545A5 (enExample)
JP2016121196A5 (enExample)
JP2020529994A5 (enExample)
JP2014513110A5 (enExample)
JP2018519323A5 (enExample)
JP2019535672A5 (enExample)
JP2017538689A5 (enExample)
JP2012529535A5 (enExample)
JP2014015465A5 (enExample)
JP2016540051A5 (enExample)
JP2017530959A5 (enExample)
JP2014193925A5 (enExample)
JP2014507455A5 (enExample)
JP2017522277A5 (enExample)
JP2009542595A5 (enExample)
JP2017523225A5 (enExample)
JP2020521767A5 (enExample)